Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body JJ, Brandi ML, Brown J, Confavreux C, Cortet B, Drake M, Ebeling P, Eriksen EF, Fuleihan GE, Guise TA, Harvey NC, Kurth A, Langdahl B, Lems W, Matijevic R, McCloskey E, Nappi R, Palacios S, Pfeiler G, Reginster JY, Rizzoli R, Santini D, Tuzun S, Poznak CV, Villiers T, Zillikens MC, Coleman R.
Hadji P, et al. Among authors: biver e.
J Bone Oncol. 2025 Jun 11;53:100694. doi: 10.1016/j.jbo.2025.100694. eCollection 2025 Aug.
J Bone Oncol. 2025.
PMID: 40726588
Free PMC article.
Review.